rule

drug

Anavex Life Sciences Corporation

wait

Seems crazy to me to unjust approvals that are going on while we wait on legitimate results!!!

But why wait 3 years with that when Anavex 50mg dose is likely better! !

So, if one waits months for an answer and then has to resubmit to another journal it can hold things up.

This is a shitshow till data is presented.

loss

but  losses  and  disappointment  with  Missling.

$AVXL Took my $250 loss and Got out guys too much noise not enough action.

but was faked by the move and held them to expiration and had to book a loss of $19,000.

shareholder

The krout has proven to be an a hole toward shareholders.

Missling is a greedy pig, doesnt see the bad he does by delaying intentionally, not only to shareholders,

i am telling for years that we need to fire that shitty guy just here to full his pockets without any consideration for his shareholders.

.this guy doesnt respect his shareholders and he must be sue for that.

$AVXL fire Missling, he has been here 9 years and done nothing to drive shareholder value other than BS hype

$AVXL why does the company not believe they are beholden to their shareholders?

$AVXL Unfortunately the Investorshub AVXL board has deteriorated to the point that it is basically a board consisting of almost entirely FUD with almost more bashers than true shareholders.

Messling is grossly deficient in anticipating the expectations of shareholders and the market.

$AVXL as corporate shareholder, I have sent an email on dec. 21st and a friendly reminder yesterday to IR - no response yet !!

One hand he says he care for shareholder value, on other hand he is purposely not sharing updates.

shareprice

$AVXL missling next time should change a few letters when hiring and SP will improve: from FDA to FBI former employee.

$AVXL Every time Missling speaks, the SP tanks…..amateurish communication, unbelievable.

It&#39;s stupid, it wastes time (and $$$) and it leaves the company vulnerable with a supressed SP.

Based on Rett alone, SP is well under 100$, sorry to bust your ballown,but please try to stay realist and keep a little credibility!

$AVXL The sp is wrong there must be a glitch

$AVXL not that i am happy with the SP overall

$AVXL Until you realize that and admit that the presenter screwed up in rushing the presentation the SP will stay where it’s at

$AVXL wandering when we will cross ANVS SP ;) 
never again!!!!

$AVXL we didnt cross ANVS SP yet, no good haha!

show

Take your money from this shit show and deposit in your bank account.

What an absolute unregulated criminal shit show this market has become.

Missling shows poor judgement and is not suited to be ceo.

SHOWS THE EXTREME WEAKNESS AND  DISTRESS THE STOCK IS UNDER.

but need more time to evaluate and announce a conference call for Monday instead we have a shit show.

This is one of those stocks that make it tempting to break my own personal trading rules to take a massive position.

My gut tells me this company has discipline and is following the rules of disclosures.

- Timo grimmer is in the team 
- All endpoints of the clinical trial were reached 
 
I firmly believe that the drug works and that the CEO has done a good job no matter how much he is criticized.

we have a drug, even many drugs, good for so many indications,  to become a giant pharma, we are about to get billions in revenues.

$AVXL The improvements in the drug arm cannot be lucky. .

I&#39;m looking forward to seeing the long term AD data on ANVS and have the feeling it&#39;s going to end up being the best in class AD treatment as well.

Do not listen to any FUD this drug is the real deal.

$AVXL amazing to see the actual benefits to people and their families of this “miracle drug” as they call it

$AVXL Dr. Perry said we have a legendary drug which actually reverses AD and is safe unlike Adulhelm.

business-result

Anavex&#39;s A2-73 Blarcamesine&#39;s trial results on 2 previously completed adult phase-3 trials were highly successful.

But the company actually has never seen before wonderful results.

If results hold up, the stock will achieve massive gains.

The results were excellent on the 2 completed adult trials, and because the 3rd trial is pediatric and early on the disease, they are expected to perform even better.

Alzheimer&#39;s is the most valuable and most difficult indication and most desired lately..  and only Anavex really has some great results with a great safety record. .

The  sava  results  trounce  you  guys  🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

Sava has potential and the phase 3 results will show the truth.

trial

$AVXL amazing  avxl  still  in  singke  digits  after  a  supposedly  amazing  “pivotal”  trial  readout  🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

$AVXL The trial met both co-primary and secondary endpoints showing statistically significant reduction of clinical decline as measured by those endpoints.

$AVXL Australia trial data meets the gold standard.

2-73 has orphan designation for Rett which combined with the multiple Rett trials and it very good safety record should make it a great candidate for AA.

This company has yet to fail to meet endpoints on any trial and the thousands of papers on the MOA  eliminates fraud with science, and the company is in great fiscal shape so no shenanigans there.

patient

It can be shown that treatment bringing back independence is less costly than the nursing homes and medical staff.

$AVXL This may show why Anavex is definitely on the right path by using patients personal genetics to determine dosage.

Many claim him to be selfish and unconcerned with others, I see a different Missling, with humility and a deep concern for patients who are suffering.

Half the patients improved over baseline over 1 year.

Blarcamesine’s Phase III clinical trials show similar levels of significant improvement in communication and interaction, as patients had statistically significant improvement in the RSBQ primary endpoint of 72.2% compared to 38.5% on placebo. .

And better still for just those 85% carrying the normal SigmaR1 gene as well as for APOE2 and 3 patients.

new clinical trial results show great promise for treating early Alzheimer’s, giving renewed hope for effective treatments.

Anavex has over 760 patients that have taken it without any significant issues. .

KemPharm Inc

If the current staff is not able to get the job done, why are we still paying them?

but sho nuff in a mood about Corium not doing their job.

but still seeing plenty of reports of Azstarys availability issues at pharmacies (Coriums job).

KEEP YOUR FOCUS ON AZSTARYS AND DO YOUR DAMN JOB.

$KMPH Honest question, who keeps their high paying job and salary when you continually fail to deliver to share holders?

He’s done a bang-up job for them while shuttle cocking us!

$KMPH Richard Pascoe should be immediately fired from his phony do nothing job at Kempharm.

But yeah Corium and it&#39;s sales reps suck and are doing a bad job.

But I thought Travis was doing a good job?? !

hand

Warrants/Option have been handed out like candy on Halloween, decreasing shareholder value.

In mentioning the changes and additions, I noticed he didn&#39;t mention all these options/warrants they handed out reducing shareholder value.

We hand it over to Corium and they completely drop the ball and sales suck.

I went all in on kmph, and for the first time in a while, I don&#39;t feel great about the cards in my hand.

Create a new position or something to hand hold Perrys dumbass through this.

$KMPH Too bad Azstarys isn’t a schedule 19 drug, KemPharm could REALLY hand out their medications today 😁

$KMPH I think it’s hysterical that The Board stated that they bring quality &amp; experience meanwhile the truth shows another picture.

but too small (market cap &amp; volume wise) for me

Please send Travis &amp; Laduane to investor presentation school or get someone on the call who gets importance of presentation.

Travis sounded like he was underwater and hungover, LaDuane sounded sheepish, and the Q&amp;A was like a sprint.

So far board &amp; mgmt have proven weak.

$KMPH too many whiners &amp; bitches here

Maybe you should have put out a disclaimer that past  performance does not indicate future results?

The top line results were written in scientific gibberish.

If NDA submission was next quarter no one would be selling off before that catalyst. Disappointing.

$KMPH 
We need better results from Corium- NOW.

Two more quarters is a hard turkey to swallow when you’ve been waiting 14. #annualholidaymicklecuck

Unfortunately  the boost for KMPH is nullified by Travis&#39;  extension of 2 more quarters of dullness

This is a 2 quarter delay, that definitely sucks,

But  at this moment it is hard for me to accept the fact that we are delayed by 2 quarters.

product

Crappy calls are a by product of all this.

Told you this was dead money with that horrible management team and generic product.

Gotta make sure they not jacked up on their own product!

“Soccer moms” rule and once Mr. and Mrs. Joe Plumber learns that they can get all the benefits and virtually no side-effects of typical ADHD meds, I believe that Azstarys will practically sell itself.

It is just because it works - better than any other adhd drug!!!

New treatments and product launches: The development and launch of new and innovative treatments for ADHD, such as extended-release formulations and combination products, is also driving market growth.

$KMPH 

I dub thee Azstarys a wonder drug.

What a great time to have an up and coming better drug.

Second, Pascoe has a choice of many, many drugs to pluck away for a song. Many!!!

But I see the drug shortage is helping  new drugs across the board and Azstarys did better since it is better among all those, imo.

$KMPH we are, qualified, the best ADHD drug on the market; not perfect,

$KMPH Cash position is outstanding, helped by a very efficient burn rate, and pipeline is advancing with 2 drugs that will have significant events in Q3 2023, and sales royalties from Corium will start ramping up in Q1.

growth

Add in a little growth, and Zevra is in the black by Q4.

The manufacturing, marketing and distribution ARE in place and the script numbers ARE showing very solid growth.

$KMPH Quite impressive growth in scripts!

This is the script growth I&#39;ve been waiting for.

$KMPH This week we have MoM script growth, 24%, and YoY script growth, 748%. Nice!

No wonder we are seeing the exponential sales growth! !

news

The good news is that once our catalysts hit, this will all be water under the bridge ✌🏻

$KMPH https://twitter.com/zevratx/status/1629141771887300616?s=46&amp;t=mKynV6sCCjZ8XQfM2ymhxA

Great news!! !

Nevertheless good news, as it means the previous script number wasn&#39;t an outliner in the other direction either.

however like $KMPH all good news as a company with tons of potential.

And 4 year study is complete that&#39;s great news.

market

The market futures (so far) are looking positive on a Monday?

I am pleased with the SP! !🫡
(Especially on a Red Market day)

Good thing the market as a whole is thriving today, 🤣.

This will be a winner take all market and it feels good to have chosen the right horse.

but now we have new market conditions we can only dream about.

$kmph Jumped back i pre market for 1k starter 5.40&#39;s  scripts this week are a blowout!

$KMPH Well if the market is voting on hires Gallo is a 👍 😂

but I also believe the market is full of opportunities nowodays.

Akebia Therapeutics Inc.

board

Lack of integrity he said to people here TBLT will go to 1.22 prereverse split.. 183 pathetic scam, he said from his heart please just kick his ass out of your boards..

$AKBA Going to be disappointment on board today.

This board is a dumpster fire filled with a bunch of amateurs who have no clue how biotech regulatory processes actually work.

So much BS on the board I don’t even wanna go through it to find the posts of substance.

Idiots on this board only wanting to make money and don&#39;t care about the safety issues.

Whole army of paid clowns appearing, board is poisoned.

$AKBA this board sucks today.. so much garbage and random people

$AKBA The current optimism of this board suddenly has me uneasy!!

When the board starts acting like this, it’s never a good sign.

but already looking like another big mistake to add to my list of big mistakes..!

$AKBA Definitely doesn’t look good, big volume!

$AKBA Company is one big failure after another.

$AKBA fukk i hate this feeling of fomo, so sad i didnt load up big sub 0.3, i would love to stack up now

If there really are big dark pool buys, Something is definitely up.

$AKBA  not even trying to expect something big.

cancer

Hazard ratios for Dapro quite bad fri malignancy, skin premalignant disorders, hypoplastic anemias, breast malignancy tumors, colorectal, prostrate, and especially renal neoplasms.

In contrast, in the NDD population, daprodustat appears to have several other important risks in addition to the risks of heart failure and bleeding gastric erosions.

Their hazard ratios are much higher than 1 meaning that very much Dapro has a propensity to cancer compared to esas.

level

$AKBA I see who apparently accept and like free speech being subjected to this level of personal attacks.

You’ll know because all the scratches will be hub cap level!

$AKBA at adcom do u know if there was any word of why gsk limited their Hb levels to essentially 10.5 not even 11 whereas other drugs vad and Roxa went up to 12 for Hb thusly gsk DD artificially looks a lot safer than it really is.

trap

Was it a bear trap by JB, or is he playing games again?

$AKBA pre-market is a Bull trap 
 
In my opinion and no advice.

Never have to worry about progressive , liberal crazy rules that allow tenants to live for free.

Two (2) other drugs, each growing revenue steadily.

since then the drug I&#39;m invested in has received a positive opinion in the entire European market of 27 countries.

but clearly the drug is not toxic.. period!

Just like how pizza is a beloved and convenient food option for parties, vadadustat is a better and more convenient treatment option for anemia associated with chronic kidney disease compared to current treatments.

Vadadustat is a better and more convenient treatment option for anemia associated with chronic kidney disease compared to current standard of care therapies.

Vadadustat may hit the ground running and never look back, particularly given that it may be the superior drug.

$AKBA I worked at a major hospital in NYC and trust me, this drug is needed.

takes a LITTLE BIT more time very very well worth it …” Was Butler telegraphing how much time is left for the release of news that will create a parabolic move?

$AKBA when we get good news im getting  my lady pregnant!!!!. .again!!

I’m assuming this one will be very positive with EU partnership news.

seem really cheap with all the potential news coming. .

That would fry any naked short and short and would shoot up stock price to the floor it should be at, with this positive chmp and soon to be formal ema approval news, that is $5 a share, minimum.

And some are saying oh its just an opinion, this is actually fantastic news for us and will open the door to other countries for approval and HOPEFULLY the US fda will approve it.

share

Shares gained +283.6% since the last report https://tinyurl.com/y6823mqe

There goes all the compliance problems in one straight shot and those shares would be worth a ton more.

I have about 234k shares and im already up 120%

$AKBA - great news, 

Ended up getting 60,500 shares for just under $40k in my lotto account.

$AKBA Loved seeing my shares in the green for a few minutes.

$AKBA What a great time to add a few more shares.

Im up around 190% and i stil havnt sold a single share

$AKBA great day, actually great week, will not sell or trim a single share until $3+ 
 
I have great confidence in her for another 300%+ 
 
.26 --&gt; 3.00+, what a biotech small cap beauty!

$AKBA I keep buying 10 and 20 shares lol I have like 50 usd of buy power left 💪

YouTube link in my profile bio. Arc community is a helpful and friendly community filled with triple digit track record traders &amp; educational content, free community room (link in bio)

This is quite good. https://www.chartmill.com/stock/quote/AKBA/fundamental-analysis?key=a33c7a6e-2162-4da3-a2d6-37296dc486fb&amp;utm_source=stocktwits&amp;utm_medium=FA&amp;utm_content=AKBA&amp;utm_campaign=social_tracking

Vadadustat DD met efficacy &amp; safety endpoints.

Also, don’t forget Vadadustat DD met efficacy &amp; safety endpoints.

&amp; if that takes LITTLE BIT more time … very, very well spent.

concerning Vadadustat will be best outcome for us (Akebia, AKBA) &amp; product (Vadadustat) &amp; he is very pleased,

The Q&amp;A employs terms such as “multiple commercial parties, deal, best outcome for us &amp; product, little bit of time, very pleased.” The Q&amp;A also uses “it’s” or “it” four times and “process” five times.

Call, Butler answered Robert Hatlett’s (industry analyst) question by using following terms &amp; words: multiple commercial parties, best outcome for us/product, little bit of time, very pleased.

CHMP positive opinion is very value creating for us &amp; having an authorization creates more value … ultimately as you get to deal.

Top Stocks matching your search for "rules drugs"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Mar, 1, 2023

Nov, 30, 2022

KMPH

KemPharm Inc

-26.64%

$5.63 - $4.13

Jan, 1, 2023

Divihomes is Now Live

AKBA

Akebia Therapeutics Inc.

-38.05%

$1.13 - $0.70

Dec, 10, 2022

AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Mar, 1, 2023

Nov, 30, 2022

KMPH

KemPharm Inc

-26.64%

$5.63 - $4.13

Jan, 1, 2023

AKBA

Akebia Therapeutics Inc.

-38.05%

$1.13 - $0.70

Dec, 10, 2022